The facility is equipped with the latest state-of-the-art technology.Continue reading
Gedeon Richter Plc.’s partner, Fuji Pharma Co., Ltd. has received marketing approval for the combination tablet Alyssa, developed in Japan. The approval triggers a milestone payment of EUR 10 million for Estetra SRL, a 100% owned subsidiary of Richter, the Hungarian pharmaceutical company announced on the website of the Budapest Stock Exchange.
The Alyssa combination tablet is a product for the treatment of dysmenorrhea (painful menstruation characterized by severe and frequent cramps) containing a natural estrogen (Estetrol), for which Fuji has acquired marketing rights in Japan and the Association of Southeast Asian Nations (ASEAN) region from Estetra SRL.
Estetrol is a new active ingredient in Japan and has been confirmed to selectively act on estrogen receptors, and this selectivity is expected to provide a variety of benefits for patients.
Fuji plans to launch the combination tablet with trade name Alyssa to provide a new treatment option for dysmenorrhea patients.
The active ingredient Estetrol was developed by Belgian company Mithra. Richter announced in June this year that it had agreed to buy some of the Belgian assets of Mithra and its subsidiary. With the transaction, 100% of the shares in Estetra and Neuralis and Mithra’s R&D capability and know-how, including exclusive rights to Estetrol, were transferred to Richter.
Via MTI, Featured image: Hungary Today